Table 2.
Effects of AT4R and FoxO1 on left ventricular function and dimension in 5 groups of mice of the second part in vivo experiment
| DM | Ang IV | Ang IV+ Divalinal | AS | Ang IV+AS | |
|---|---|---|---|---|---|
| LVEF (%) | 41.45 ± 3.50 | 63.34 ± 2.20*** | 43.79 ± 5.58## | 60.54 ± 2.72*** | 67.76 ± 2.25*** |
| FS (%) | 25.72 ± 1.51 | 36.87 ± 2.09** | 28.21 ± 2.62# | 38.56 ± 1.52*** | 41.97 ± 2.93*** |
| E/A | 0.87 ± 0.06 | 1.36 ± 0.08*** | 1.00 ± 0.18# | 1.27 ± 0.08** | 1.45 ± 0.13** |
| E'/A' | 0.59 ± 0.07 | 1.29 ± 0.13** | 0.80 ± 0.15# | 1.51 ± 0.10*** | 1.48 ± 0.13*** |
| LVEDD (mm) | 3.73 ± 0.12 | 3.19 ± 0.09** | 3.67 ± 0.08## | 3.20 ± 0.10** | 3.08 ± 0.11*** |
Ang IV: Angiotensin IV; AS: FoxO1 inhibitor AS1842856; E/A: the ratio of the early to late diastolic mitral inflow velocities; E'/A': the ratio of the early to late diastolic mitral annular velocities; FS: fractional shortening; LVEF: left ventricular ejection fraction; LVEDD: left ventricular end-diastolic diameter. **p < 0.01, ***p < 0.001 vs. DM group; #p < 0.05, ##p < 0.01 vs. Ang IV group. n ≥ 8 per group.